Haura EB - Search Results

1

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).

Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, Lau CL, Sholl L, Takebe N, Moscow JA, Shapiro GI, Jänne PA, Oxnard GR. Bertino EM, et al. Among authors: haura eb. Clin Cancer Res. 2021 Mar 15;27(6):1604-1611. doi: 10.1158/1078-0432.CCR-20-4084. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376097 Free PMC article. Clinical Trial.

2

Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies.

Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Haura EB, et al. Clin Lung Cancer. 2004 Sep;6(2):113-22. doi: 10.3816/CLC.2004.n.025. Clin Lung Cancer. 2004. PMID: 15476597 Review.

3

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Haura EB, et al. Clin Cancer Res. 2005 Dec 1;11(23):8288-94. doi: 10.1158/1078-0432.CCR-05-0827. Clin Cancer Res. 2005. PMID: 16322287

4

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.

Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Song L, et al. Among authors: haura eb. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620. Cancer Res. 2006. PMID: 16740687

5

Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.

de Lima Lopes G Jr, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. de Lima Lopes G Jr, et al. Cancer. 2007 Apr 1;109(7):1413-9. doi: 10.1002/cncr.22522. Cancer. 2007. PMID: 17326096 Free article. Clinical Trial.

6

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Simon G, et al. J Clin Oncol. 2007 Jul 1;25(19):2741-6. doi: 10.1200/JCO.2006.08.2099. J Clin Oncol. 2007. PMID: 17602079 Clinical Trial.

7

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Simon GR, et al. Among authors: haura eb. Cancer. 2008 May 1;112(9):2021-9. doi: 10.1002/cncr.23360. Cancer. 2008. PMID: 18300255 Free article. Clinical Trial.

8

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.

9

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Haura EB, et al. J Clin Oncol. 2010 Mar 10;28(8):1387-94. doi: 10.1200/JCO.2009.25.4029. Epub 2010 Feb 8. J Clin Oncol. 2010. PMID: 20142592 Free PMC article. Clinical Trial.

10

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. Haura EB, et al. Clin Cancer Res. 2010 Apr 15;16(8):2450-7. doi: 10.1158/1078-0432.CCR-09-1920. Epub 2010 Mar 23. Clin Cancer Res. 2010. PMID: 20332327 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

241 results

Search Page